CD19-TRAIL single treatment was efficient in reducing leukemic burden of BCP-ALL PDX cells from different patients in xenografted NSG-mice and was well tolerated by treated animals, which to our knowledge has not been reported for other CD19 antibody-TRAIL constructs to date. This evidence concerns the gene TNFSF10 and acute lymphoblastic leukemia.